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Objective. Candidate gene and genome-wide asso-
ciation studies have identified several disease suscepti-
bility loci in lupus patients. These studies have largely
been performed in lupus patients who are Asian or of
European ancestry. This study was undertaken to ex-
amine whether some of these same susceptibility loci
increase lupus risk in African American individuals.
Methods. Single-nucleotide polymorphisms tag-
ging 15 independent lupus susceptibility loci were geno-
typed in a set of 1,724 lupus patients and 2,024 healthy
controls of African American descent. The loci examined
included PTPN22, FCGR2A, TNFSF4, STAT4, CTLA4,
PDCD1, PXK, BANK1, MSH5 (HLA region), CFB (HLA
region), C8orf13-BLK region, MBL2, KIAA1542, ITGAM,
and MECP2/IRAK1.
Results. We found the first evidence of genetic
association between lupus in African American pa-
tients and 5 susceptibility loci (C8orf13-BLK, BANK1,
TNFSF4, KIAA1542, and CTLA4; P  8.0  106,
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P  1.9  105, P  5.7  105, P  0.00099, and
P  0.0045, respectively). Further, we confirmed the
genetic association between lupus and 5 additional
lupus susceptibility loci (ITGAM, MSH5, CFB, STAT4,
and FCGR2A; P  7.5  1011, P  5.2  108,
P  8.7  107, P  0.0058, and P  0.0070, respec-
tively), and provided evidence, for the first time, of
genome-wide significance for the association between
lupus in African American patients and ITGAM and
MSH5 (HLA region).
Conclusion. These findings provide evidence of
novel genetic susceptibility loci for lupus in African
Americans and demonstrate that the majority of lupus
susceptibility loci examined confer lupus risk across
multiple ethnicities.
Systemic lupus erythematosus (SLE) is a systemic
autoimmune disease characterized by autoantibody pro-
duction, abnormalities of immune system function, and
damage in several organs. Although the exact pathogen-
esis of SLE is unknown, there is strong evidence for
contributions of both genetic risk factors and environ-
mental events, which lead to a break in immunologic self
tolerance (1). SLE is 9 times more common in women
than in men (2), particularly during the childbearing
years. There are also marked disparities in SLE inci-
dence and prevalence worldwide; SLE prevalence varies
among different ethnic and geographic populations (3).
SLE is 4 times more common in people of African
American ancestry than in those of European ancestry
(4,5). In addition, African Americans have a markedly
increased risk of developing lupus nephritis relative to
European Americans (5). The ethnic and genetic hetero-
geneity of SLE may contribute to the complexity of its
clinical manifestation.
Recent genome-wide association studies (GWAS)
and candidate gene studies have identified30 SLE risk
alleles that are common in both populations of Euro-
pean ancestry and populations of Asian ancestry (6,7).
These include genes encoding proteins important for
adaptive immunity and the production of autoantibodies
(HLA alleles, BLK, BANK1, and PTPN22) (8–10), pro-
teins with roles in innate immunity and interferon (IFN)
signaling (ITGAM, STAT4, and IRF5) (8,11–13), and
genes involved in DNA methylation (MECP2) (14),
among others.
In this study, we analyzed 3,462 African Ameri-
can patients with lupus and controls and 286 Gullah
African American patients with lupus and controls for
genetic association with polymorphisms within 15 con-
firmed lupus susceptibility loci (8,9,11–22). We con-
firmed that HLA, STAT4, FCGR2A, and ITGAM are
associated with SLE and provided evidence of genome-
wide significance of the association of HLA and ITGAM
in African American patients with lupus. Further, we
described, for the first time, genetic associations be-
tween C8orf13-BLK, BANK1, TNFSF4, CTLA4, and
KIAA1542 and lupus in African American patients.
PATIENTS AND METHODS
Patients and controls. Two independent SLE case–
control cohorts were recruited through a multicenter collabo-
ration within the US and assembled at the Oklahoma Medical
Research Foundation. The study included a total of 3,462
African American samples (1,569 SLE patients and 1,893
healthy controls) and 286 Gullah African American samples
(155 SLE patients and 131 healthy controls) (23). Gullah
subjects have a considerably lower level of non-African genetic
admixture when compared to other African American popu-
lations. All cases fulfilled the American College of Rheuma-
tology criteria for the classification of SLE (24). Informed
consent was obtained from all subjects. The study was ap-
proved by the institutional review boards at each of the
participating institutions.
Genotyping. Genotyping was performed using the
Illumina Custom Bead system on an iSCAN instrument as
part of a large lupus candidate gene association study, in order
to reduce the cost of genotyping and maximize the sample
size. The following single-nucleotide polymorphisms (SNPs)
within 15 confirmed susceptibility loci for SLE were used:
rs2476601 (PTPN22), rs1801274 (FCGR2A), rs2205960
(TNFSF4), rs7574865 (STAT4), rs231775 (CTLA4),
rs11568821 (PDCD1), rs6445975 (PXK), rs10516487 (BANK1),
rs3131379 (MSH5 within the class III major histocompatibility
complex [MHC] region), rs1270942 (CFB within class III
MHC), rs13277113 (C8orf13-BLK region), rs1800450 (MBL2),
rs4963128 (KIAA1542), rs1143679 (ITGAM), and rs17435
(MECP2/IRAK1) (8–22,25). IRF5, a known SLE susceptibility
gene, was not examined in the present study because it was
extensively studied in an African American cohort with lupus
that included some of the samples included in this study (26).
Similarly, the genetic association between IL21 and lupus in
African American patients has recently been demonstrated
(27). These SNPs were selected because they tag independent
lupus susceptibility loci in lupus patients of European ancestry.
In addition, 161 admixture informative markers were geno-
typed and evaluated in our samples. The admixture informa-
tive markers were selected to distinguish 4 continental ances-
tral populations: Africans, Europeans, American Indians, and
East Asians (28–32).
Data analysis. Samples with a genotype success rate of
90% were excluded from the analysis. A total of 19 African
American samples and 1 Gullah sample were removed due to
a low genotype success rate. The remaining samples were then
evaluated for duplicates or related individuals, and one indi-
vidual from each pair was removed if the proportion of alleles
with shared identity by descent was 0.4 in African American
samples or 0.35 in Gullah samples (resulting in the exclusion
of 57 African American and 8 Gullah samples). Samples with
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increased heterozygosity (5 SD from the mean) were then
removed from the analysis. Samples were assessed for mis-
matches between reported sex and genetic data, and individu-
als with sex discrepancies were removed from the analysis.
Finally, genetic outliers were removed from further analysis as
determined by principal components analysis (Figure 1) and
admixture estimates using AdmixMap software (33–35). A
total of 30 genetic outliers were removed from the African
American sample set, and 1 genetic outlier was removed from
the Gullah sample set. After quality control, a total of 1,527
cases and 1,811 controls of African American descent and 152
cases and 123 controls of Gullah descent were included in
subsequent analyses.
For each sample set analyzed, markers with a genotype
success rate of90%, Hardy-Weinberg equilibrium of0.001,
or minor allele frequency (MAF) of0.01 were excluded from
further analysis. All 15 markers were analyzed in the African
American individuals, and 13 markers passed the inclusion
threshold and were analyzed in the Gullah participants (2
SNPs were excluded due to MAF of 0.01).
To test for genetic association in SLE, we performed
logistic regression, as implemented in Plink (36). Allele fre-
quency differences between cases and controls were calcu-
lated with adjustment for the ancestry estimates provided by
AdmixMap. Analysis was also performed separately with ad-
justment for the first 3 principal components. The results
obtained by either method were very similar, and data adjusted
for principal components are reported herein. Inflation factors
() were calculated using “null” ancestry informative markers.
Pooled odds ratios (ORs) were estimated using StatsDirect,
version 2.4.6. The meta-analysis was conducted using standard
methods based on the Cochran-Mantel-Haenszel test (37).
The Breslow-Day test (38) was performed for all SNPs to
assess the heterogeneity of the ORs in different populations.
RESULTS
Population structure analyses showed that the
African ancestry and European ancestry was 81.3% and
15.7%, respectively, among the African American sam-
ples, with an inflation factor  of 1.32, and 90% and
7.2% among the Gullah samples, with an inflation factor
 of 1.10. Therefore, all results presented herein were
adjusted for principal components.
We genotyped 15 SNPs, tagging 15 independent
susceptibility loci previously established in patients of
European ancestry with SLE, in 2 independent cohorts
of African descent. After excluding SNPs and individuals
that did not pass our quality control standards, a total of
15 and 13 SNPs were analyzed in the African American
and Gullah samples, respectively, in a total of 1,679 SLE
patients and 1,934 controls. Two SNPs in the Gullah
samples were excluded after MAF quality control
(PDCD1 [rs11568821] and PTPN22 [rs2476601]).
Within the African American samples, we found
evidence of significant genetic association between SLE
and 10 loci after correction for the first 3 principal
components. An association was observed for ITGAM
(P  1.9  109, OR 1.57), MSH5 (P  4.1  108, OR
1.65), CFB (P  7.1  107, OR 1.63), C8orf13-BLK
(P  6.4  106, OR 1.36), BANK1 (P  5.9  105,
OR 0.78), TNFSF4 (P  0.00056, OR 1.44), KIAA1542
(P  0.0020, OR 0.86), FCGR2A (P  0.012, OR 0.88),
Figure 1. Scatter plots generated by the first 2 components of a
principal components analysis of the African American samples (A)
and the Gullah samples (B). The x-axis shows principal component 1
(PC1), and the y-axis shows principal component 2 (PC2).
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STAT4 (P  0.012, OR 1.19), and CTLA4 (P  0.013,
OR 1.14) (Table 1).
Genetic association analysis of the Gullah sam-
ples revealed only 2 markers associated with SLE,
TNFSF4 (P  0.0015, OR 4.99) and ITGAM (P 
0.0080, OR 1.97) (Table 2). Notably, these 2 markers
were also associated with SLE in the African American
participants.
Next, a meta-analysis was performed using the
African American and Gullah data sets and the 13 SNPs
that could be evaluated in both sample sets (Table 3).
The meta-analysis of these genetic markers in the
African American and Gullah data sets using the
Mantel-Haenszel test under a fixed-effects model re-
vealed a significant association with SLE for FCGR2A
(Pmeta  0.0070, ORmeta 0.88), TNFSF4 (Pmeta  5.7 
105, ORmeta 1.51), STAT4 (Pmeta  0.0058, ORmeta
1.20), CTLA4 (Pmeta  0.0045, ORmeta 1.15), BANK1
(Pmeta 1.9 10
5, ORmeta 0.78), MSH5 (Pmeta 5.2
108, ORmeta 1.63), CFB (Pmeta  8.7  10
7, ORmeta
1.60), C8orf13-BLK (Pmeta  8.0  10
6, ORmeta 1.34),
KIAA1542 (Pmeta  0.00099, ORmeta 0.86), and ITGAM
Table 1. Genetic associations between 15 lupus susceptibility loci and lupus in African Americans, adjusted for principal components*




(no. of minor alleles/
no. of major alleles)
MAF in controls
(no. of minor alleles/
no. of major alleles) OR (95% CI) P
PTPN22 rs2476601 1 114179091 A 0.018 (56/2,996) 0.014 (50/3,568) 1.31 (0.90–1.92) 0.16
FCGR2A rs1801274 1 159746369 A 0.429 (1,298/1,726) 0.460 (1,645/1,931) 0.88 (0.80–0.97) 0.012
TNFSF4 rs2205960 1 171458098 A 0.070 (213/2,839) 0.049 (179/3,441) 1.44 (1.17–1.76) 0.00056
STAT4 rs7574865 2 191672878 A 0.168 (505/2,503) 0.145 (512/3,022) 1.19 (1.04–1.36) 0.012
CTLA4 rs231775 2 204440959 G 0.392 (1,193/1,849) 0.363 (1,310/2,302) 1.14 (1.03–1.26) 0.013
PDCD1 rs11568821 2 242442585 A 0.026 (78/2,956) 0.020 (69/3,441) 1.31 (0.94–1.81) 0.11
PXK rs6445975 3 58345217 A 0.429 (1,310/1,742) 0.441 (1,592/2,016) 0.95 (0.86–1.05) 0.32
BANK1 rs10516487 4 102970099 A 0.197 (599/2,435) 0.239 (859/2,741) 0.78 (0.70–0.88) 5.9 105
MSH5 rs3131379 6 31829012 A 0.101 (308/2,744) 0.064 (231/3,389) 1.65 (1.38–1.98) 4.1 108
CFB rs1270942 6 32026839 G 0.085 (260/2,794) 0.054 (195/3,427) 1.63 (1.34–1.97) 7.1 107
C8orf13-BLK rs13277113 8 11386595 A 0.172 (520/2,506) 0.131 (467/3,111) 1.36 (1.19–1.55) 6.4 106
MBL2 rs1800450 10 54201241 A 0.032 (98/2,952) 0.029 (104/3,514) 1.12 (0.84–1.48) 0.45
KIAA1542 rs4963128 11 579564 A 0.419 (1,260/1,746) 0.458 (1,621/1,917) 0.86 (0.78–0.95) 0.0020
ITGAM rs1143679 16 31184312 A 0.153 (467/2,583) 0.104 (375/3,233) 1.57 (1.36–1.82) 1.9 109
MECP2 rs17435 23 152965174 A 0.393 (1,151/1,778) 0.384 (1,166/1,873) 1.05 (0.95–1.17) 0.35
* Odds ratios (ORs) represent differences in the minor allele frequency (MAF) between cases and controls in each locus. SNP  single-nucleotide
polymorphism; 95% CI  95% confidence interval.
† Determined using Genome Build 36.3.
Table 2. Genetic associations between lupus susceptibility loci and lupus in Gullah subjects, adjusted for principal components*




(no. of minor alleles/
no. of major alleles)
MAF in controls
(no. of minor alleles/
no. of major alleles) OR (95% CI) P
FCGR2A rs1801274 1 159746369 A 0.430 (129/171) 0.476 (117/129) 0.85 (0.60–1.18) 0.33
TNFSF4 rs2205960 1 171458098 A 0.092 (28/276) 0.020 (5/241) 4.99 (1.85–13.43) 0.0015
STAT4 rs7574865 2 191672878 A 0.150 (44/250) 0.107 (26/218) 1.39 (0.85–2.29) 0.19
CTLA4 rs231775 2 204440959 G 0.372 (113/191) 0.303 (74/170) 1.34 (0.94–1.91) 0.11
PXK rs6445975 3 58345217 A 0.398 (121/183) 0.390 (96/150) 1.03 (0.73–1.44) 0.87
BANK1 rs10516487 4 102970099 A 0.211 (64/240) 0.262 (64/180) 0.74 (0.50–1.10) 0.14
MSH5 rs3131379 6 31829012 A 0.053 (16/288) 0.045 (11/235) 1.19 (0.55–2.60) 0.66
CFB rs1270942 6 32026839 G 0.043 (13/291) 0.037 (9/237) 1.18 (0.50–2.75) 0.71
C8orf13-BLK rs13277113 8 11386595 A 0.153 (46/254) 0.139 (34/210) 1.11 (0.68–1.80) 0.69
MBL2 rs1800450 10 54201241 A 0.016 (5/299) 0.016 (4/242) 1.02 (0.27–3.90) 0.98
KIAA1542 rs4963128 11 579564 A 0.389 (115/181) 0.438 (105/135) 0.82 (0.58–1.15) 0.25
ITGAM rs1143679 16 31184312 A 0.191 (58/246) 0.110 (27/219) 1.97 (1.19–3.26) 0.0080
MECP2 rs17435 23 152965174 A 0.308 (89/200) 0.333 (76/152) 0.85 (0.57–1.27) 0.42
* Two of the 15 single-nucleotide polymorphisms (SNPs) examined in the study were not included in this analysis due to low minor allele
frequencies (MAFs) in the Gullah subjects. Odds ratios (ORs) represent differences in the MAF between cases and controls in each locus. 95% CI
95% confidence interval.
† Determined using Genome Build 36.3.
3496 SA´NCHEZ ET AL
(Pmeta  7.5  10
11, ORmeta 1.60) (Table 3). Impor-
tantly, our data show that the risk alleles in the genetic
associations we detected in lupus patients of African
descent are the same as the risk alleles previously found
in patients of European ancestry (Table 3).
DISCUSSION
The genetic heterogeneity between populations
of different ethnicities has been suggested to be impor-
tant in SLE risk (39), emphasizing the need for further
studies in different populations. It has been consistently
shown that patients of African descent have more severe
lupus and a higher prevalence of lupus than those of
European ancestry (4,5). In an attempt to determine
whether some of the lupus susceptibility genes identified
in patients of European ancestry also confer disease
susceptibility in populations of African descent, we
studied 2 independent African American populations
from the US and genotyped common variants that
represent 15 of the most established genetic susceptibil-
ity loci for lupus.
We found evidence of association between SLE
and 10 genetic variants in American patients of African
descent. A meta-analysis of both of the African-derived
populations that were examined revealed associations
with genome-wide significance at 2 loci, ITGAM and
MSH5 (in the HLA region).
The most significant effect was observed for a
nonsynonymous SNP in the third exon of the ITGAM
gene (rs1143679 [ORmeta 1.60, Pmeta  7.5  10
11).
This variant was previously shown to be associated with
SLE in populations of African descent (17) and has been
hypothesized to disturb the interaction between ITGAM
and its ligands. Another genetic association that was
established with genome-wide significance in the present
study was within the HLA region in the MSH5 gene
(rs3131379 [ORmeta 1.63, Pmeta  5.2  10
8). It has
previously been shown that the HLA region confers risk
for lupus in African Americans (40–42), but this is the
first study to establish this association with specific
independent variants within this region and with
genome-wide significance.
The next strongest associations were with 2
nonsynonymous polymorphisms (rs13277113 and
rs10516487) located in the C8orf13-BLK locus and the
BANK1 gene, respectively (ORmeta 1.34, Pmeta  8.0 
106 and ORmeta 0.78, Pmeta 1.9 10
5, respectively).
C8orf13-BLK and BANK1 are involved in B cell
receptor–mediated signaling and B cell development
(43,44). Although no functional variant has been iden-
tified in C8orf13-BLK, the risk alleles of the rs13277113
SNP correlate with low levels of messenger RNA for
BLK and high levels of C8orf13, raising the possibility
that either of these two effects could be related to SLE
(8). In addition, it has been hypothesized that
rs10516487 could potentially alter the affinity of BANK1
for inositol 1,4,5-trisphosphate receptor, altering B cell
signaling in SLE patients (9). The TNFSF4 gene also
Table 3. Meta-analysis of genetic associations in the African American samples and Gullah samples,
adjusted for principal components*
Gene SNP OR (95% CI) Pmeta Pheterogeneity
OR (95% CI) in
European-derived
populations (ref.)
FCGR2A rs1801274 0.88 (0.80–0.96) 0.0070 0.81 0.86 (0.77–0.92) (67)
TNFSF4 rs2205960 1.51 (1.24–1.86) 5.7 105 0.02 1.22 (1.15–1.30) (67)
STAT4 rs7574865 1.20 (1.06–1.37) 0.0058 0.54 1.57 (1.49–1.69) (67)
CTLA4 rs231775 1.15 (1.04–1.26) 0.0045 0.38 1.60 (1.01–2.53) (68)
PXK† rs6445975 0.96 (0.87–1.05) 0.36 0.67 0.80 (0.74–0.86) (11)
BANK1 rs10516487 0.78 (0.76–0.87) 1.9 105 0.78 0.72 (0.66–0.80) (9)
MSH5 rs3131379 1.63 (1.36–1.92) 5.2 108 0.42 2.36 (2.11–2.64) (11)
CFB rs1270942 1.60 (1.33–1.94) 8.7 107 0.47 2.35 (2.10–2.63) (11)
C8orf13-BLK rs13277113 1.34 (1.21–1.55) 8.0 106 0.42 1.39 (1.28–1.51) (8)
MBL2 rs1800450 1.11 (0.85–1.47) 0.45 0.90 1.33 (1.08–1.65) (69)
KIAA1542 rs4963128 0.86 (0.77–0.94) 0.00099 0.80 0.83 (0.79–0.88) (67)
ITGAM rs1143679 1.60 (1.37–1.83) 7.5 1011 0.40 1.78 (1.56–2.03) (17)
MECP2 rs17435 1.04 (0.94–1.16) 0.49 0.30 1.22 (1.07–1.38) (70)
* Only the 13 single-nucleotide polymorphisms (SNPs) that passed quality control measures in both
sample sets were included in this analysis. Odds ratios (ORs) represent differences in the minor allele
frequency between cases and controls in each locus. 95% CI  95% confidence interval.
† The minor allele for the PXK polymorphism rs644975 is the C allele in populations of European ancestry
and the A allele in African Americans.
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showed a strong association with SLE in African Amer-
ican patients in the present study (ORmeta 1.51, Pmeta 
5.7  105). TNFSF4 encodes the OX40 ligand, a
costimulatory molecule involved in T cell activation. A
similar association between TNFSF4 rs2205960 and SLE
has been reported in Chinese patients (45).
Two other genes that were previously found to
be associated with SLE in populations of African an-
cestry, STAT4 (rs7574865) and FCGR2A (rs1801274)
(21,46,47), were also found to be associated with SLE in
the present study (Pmeta  0.0058 for STAT4 and
Pmeta  0.0070 for FCGR2A). The FCGR2A gene is
located in a region that was previously found to be
associated with SLE through linkage studies in African
Americans (1q41) (47) and has been described as a risk
factor for lupus nephritis in this population (21).
FCGR2A is an important receptor that mediates phago-
cytic functions in different cells, and there is evidence
that FCGR2A alleles confer distinct functional capacities
to phagocytes, providing a mechanism for heritable
susceptibility to immune complex–mediated disease
(48,49).
The association between STAT4 and SLE risk
was initially reported in 2007 (13). This was subsequently
confirmed by several GWAS in Europeans and Asians
(8,11,50,51) and in an African American cohort through
high-density genotyping of STAT4 in different racial
groups (46). STAT4 encodes a transcription factor that
mediates the expression of genes in a number of key
immunologic pathways and induces relevant cytokines,
including type I IFNs, interleukin-12 (IL-12), and IL-23.
STAT4 may also play a role in the differentiation of the
potentially pathogenic Th17 T cell subset (52). Although
no functional candidate polymorphism has yet been
clearly established for STAT4, its roles in susceptibility
to several autoimmune diseases and modulating immune
functions suggest that it is an important gene in autoim-
munity.
In previous studies, no association between
CTLA4 and KIAA1542 genes and SLE in African Amer-
icans was found (53,54). However, both genes were
found to be associated with SLE in this study (Pmeta 
0.0045 and Pmeta  0.00099, respectively). The previous
studies were underpowered to detect a significant asso-
ciation in these loci due to small sample sizes compared
to the sample size in the present study. (The previous
studies included 230 SLE patients and 276 controls [53]
and 159 SLE patients and 115 controls [54].) In-
terestingly, the lupus-protective allele in rs4963128
(KIAA1542) has been associated with anti-Sm antibody
in African American patients with lupus, and in the
presence of anti-Sm, this same allele is associated with
increased serum IFN activity levels (55).
The rs6445975 SNP in the PXK gene, rs2476601
in PTPN22, rs11568821 in PDCD1, and rs1800450 in the
MBL2 gene were not associated with SLE in the popu-
lation examined in this study. The PXK and MBL2
variants have been shown to be associated with SLE in
different European cohorts (11,20); however, none of
these associations has been replicated for other ethnic
backgrounds (32,39,56–59). Previous studies of African
American patients with SLE failed to show a significant
genetic association between SLE and the PTPN22 and
PDCD1 genes (60,61). Ethnic differences in PTPN22
rs2476601 and PDCD1 rs11568821 allele frequencies
have been described (60,62). African Americans have
much lower minor allele frequencies of rs2476601
(PTPN22) and rs11568821 (PDCD1) (2% and 3%, re-
spectively) compared to individuals of European ances-
try (8% and 13%, respectively) (62). Interestingly, nei-
ther of the minor alleles of these 2 SNPs is observed
in populations of Asian descent (62–64). It is important
to note that although we did not find an association
between PTPTN22 or PDCD1 and SLE in African
Americans, our study was underpowered to detect an
association with an OR of 1.3 for PTPTN22 or PDCD1
(23% and 31%, respectively), probably due to the lower
MAF of these polymorphisms in African Americans
compared to populations of European ancestry. There-
fore, we cannot rule out a possible role of these 2 genes
in African American patients with lupus.
Figure 2. Lupus susceptibility loci that are unique to patients of
European descent and those that are shared by patients of European
descent and African American patients, determined based on the
susceptibility loci included in this study and the results of the meta-
analysis performed in the African American and Gullah sample sets.
More genetic studies are needed to explain the higher prevalence and
the more severe presentation of lupus in African Americans.
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In addition, the genetic association with rs17435
within MECP2, which tags the MECP2/IRAK1 suscepti-
bility locus that has been well established in Asian
patients and patients of European ancestry with lupus
(14,65,66), was not replicated in the populations of
African descent analyzed in the present study. How-
ever, fine-mapping and localization of the genetic effect
in this locus in multiple ethnicities is under way
(Kaufman KM, et al: unpublished observations).
The lack of genetic association between lupus in
African American patients and some of the genetic
susceptibility loci established in patients of European
ancestry could be due to a different haplotype structure,
given that causal variants for most of the genetic suscep-
tibility loci have not been identified. Another possibility
could be that some of the disease susceptibility loci
operate in some, but not all, ethnicities. Figure 2 sum-
marizes the unique and shared genetic susceptibility loci
in SLE patients of European and African ancestry.
Further studies of African American patients with lupus
are needed to identify new and possibly unique SLE
susceptibility loci in this population.
In summary, this is the first study to show a
genetic association between lupus in African American
patients and 5 loci (C8orf13-BLK, BANK1, CTLA4,
KIAA1542, and TNFSF4). In addition, we established
the genetic associations between SLE and the HLA re-
gion and between SLE and ITGAM with genome-wide
significance in African Americans. We also confirmed
the genetic association between SLE in African Americans
and STAT4 and FCGR2A.
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